Clinical Trials Logo

Hypertension clinical trials

View clinical trials related to Hypertension.

Filter by:

NCT ID: NCT05138601 Recruiting - Hypertension Clinical Trials

Remote Monitoring and Virtual Collaborative Care For Hypertension Control to Prevent Cognitive Decline Phase II

vCCC 2
Start date: November 16, 2021
Phase: N/A
Study type: Interventional

This is a randomized, controlled, pragmatic trial designed as a "type I hybrid effectiveness-implementation trial" that tests a hypertension program integrating a virtual Collaborative Care Clinic (vCCC), home blood pressure monitoring, and telehealth for lowering blood pressure (BP) in two health systems.

NCT ID: NCT05137808 Recruiting - Clinical trials for Hypertension in Pregnancy

Understanding Blood Pressure Changes After Birth

Start date: May 9, 2022
Phase:
Study type: Observational

Research Question How does maternal blood pressure respond in the postpartum period for women who had a hypertensive disorder in pregnancy? Aim To evaluate the recovery of maternal blood pressure after a pregnancy affected by new onset hypertension after twenty weeks gestation Objectives - To identify rates of persistent hypertension after pregnancies affected by HDP - To assess and compare the accuracy of HBPM against the gold standard of ABPM - To assess the maternal acceptance of HBPM and ABPM - To explore what CVD-related care information is provided at the 6-8 week GP appointment

NCT ID: NCT05133713 Recruiting - Clinical trials for Pulmonary Hypertension

Ventilation and Perfusion Scan in Pulmonary Embolism Following Catheter Directed Thrombectomy Versus Anticoagulation Alone

VQPE
Start date: April 1, 2022
Phase:
Study type: Observational [Patient Registry]

Clinical presentation of acute pulmonary embolism (PE) is complex and varied and not uncommonly involves respiratory failure with dyspnea or hypoxia. Patients with persisting signs of respiratory failure despite anticoagulation, may benefit from catheter directed thrombectomy. Additionally, patient who receive thrombectomy are likely to have a lower residual thrombus burden measurable by ventilation-perfusion (V/Q) scan, and thereby less likely to develop chronic sequela, including chronic thromboembolic pulmonary hypertension (CTEPH) and post PE syndrome.

NCT ID: NCT05129345 Recruiting - Hypertension Clinical Trials

Addressing Barriers to Achieving Cardiometabolic Disorders Prevention and Treatment Goals for PLWH in the SE US

Start date: June 7, 2022
Phase:
Study type: Observational

This study has 3 aims. Aim 1: Identify social determinants of cardiometabolic health and determine facilitators and modifiable barriers in achieving treatment goals. Aim 2: Assess PLWH knowledge, skills, and confidence for self-management of cardiometabolic disorders. Aim 3: Tailor a self-management support and education intervention with stakeholder input to address barriers to achieving treatment goals for cardiometabolic disorders in PLWH at the study sites.

NCT ID: NCT05121337 Recruiting - Hypertension Clinical Trials

Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension

GoFresh
Start date: September 30, 2022
Phase: N/A
Study type: Interventional

GoFresh is a randomized trial, testing the effects of a home-delivered DASH-patterned grocery intervention on blood pressure in Black adults, residing in Boston area urban food deserts.

NCT ID: NCT05110066 Recruiting - Clinical trials for Chronic Thromboembolic Pulmonary Hypertension

BPA vs. PEA in CTEPH

GO-CTEPH
Start date: April 1, 2024
Phase: N/A
Study type: Interventional

Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare and potentially life-threatening progressive disease that evolves from unresolved pulmonary embolism. Gold standard treatment for CTEPH is pulmonary endarterectomy (PEA) performed by skilled cardio-thoracic surgeons. Some patients may not be surgical candidates due to co-morbidities or because the vascular lesions are too distal making them technically inoperable. In these patients, balloon pulmonary angioplasty (BPA) has emerged as an effective treatment. In a subgroup of patients, the distribution of vascular lesions makes it possible to perform either BPA or PEA. There has never been a head-to head comparison of BPA with PEA. The aim of this study is therefore, to evaluate if BPA is non-inferior to PEA in patients with (CTEPH) who are eligible for both treatments.

NCT ID: NCT05109013 Recruiting - Clinical trials for Essential Hypertension

Juvenile Essential Arterial Hypertension and Vascular Function

Start date: September 1, 2021
Phase:
Study type: Observational

The main goal of this study is to investigate the association of the juvenile essential arterial hypertension with systemic micro- and macrovascular reactivity and cerebral vascular function, and to examine the potential impact of elevated oxidative stress on this associations.

NCT ID: NCT05106036 Recruiting - Hypertension Clinical Trials

Preventing Cognitive Decline by Reducing BP Target Trial

PCOT
Start date: July 11, 2022
Phase: N/A
Study type: Interventional

The PCOT study is a multi-site randomized trial of patients 70 years or older with high BP. The main goal of the study Preventing Cognitive Decline by Reducing BP Target Trial (PCOT) is to conduct a large pragmatic clinical trial (PCT) to test the hypothesis that patients who receive care with a combination of clinical decision support (CDS) and team-based care delivered in primary care practices will have better blood pressure control and a lower incidence of mild cognitive impairment and dementia than patients receiving usual medical care. Patients will be recruited from UT Southwestern Medical Center and Parkland Health & Hospital System.

NCT ID: NCT05092672 Recruiting - Clinical trials for Essential Hypertension

Physical Activity, Air Pollution, and High Blood Pressure

Start date: November 15, 2021
Phase: N/A
Study type: Interventional

The investigators are investigating the effects of traffic-related air pollution (TRAP) on the cardiovascular and pulmonary response to exercise in patients with hypertension using a real world randomized, crossover study design. Participants will be exposed to 2 conditions: a low TRAP environment and a high TRAP environment. Each exposure will consist of 30 min of moderate-intensity exercise. Cardiovascular and pulmonary health outcomes will be measured before, during, and up to 24 hours following exposures. A minimum washout period of 1 week will be used to minimize carryover effects.

NCT ID: NCT05089448 Recruiting - Hypertension Clinical Trials

Morning Versus Bedtime Dosing of Antihypertensive Medication

Start date: January 28, 2021
Phase: Phase 4
Study type: Interventional

Previous studies have shown that elevated nighttime blood pressure (BP) was more closely associated with cardiovascular mortality and morbidity than daytime and clinic BPs. With increasingly advanced technology, not only 24-hour ambulatory but also home BP monitors can be used to evaluate nighttime BP. The validation study of the Omron HEM 9601T showed that the wrist-type home BP monitor could be a suitable and reliable tool for the diagnosis and management of nocturnal hypertension. However, up to now, there is no data on home nighttime BP in Chinese patients and it is unclear if different dosing time would reduce ambulatory and home nighttime BPs differently. The investigators therefore designed a multicenter randomized clinical trial to compare between morning dosing and bedtime dosing of antihypertensive medications in the difference in nighttime, daytime and the 24-h BP reductions evaluated by both ambulatory and home BP monitoring, and in target organ protections.